BCL2 and lymphoma: One of main limitations of the successful treatment of MYC/BCL2 DH lymphoma is lack of comprehensive understanding of disease pathogenesis and mechanisms of chemotherapeutic resistance, as well as knowledge of potential therapeutic targets.